Compare Dishman Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs AUROBINDO PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA AUROBINDO PHARMA DISHMAN PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 25.1 9.9 254.4% View Chart
P/BV x 3.3 1.8 183.7% View Chart
Dividend Yield % 0.7 0.6 114.9%  

Financials

 DISHMAN PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
AUROBINDO PHARMA
Mar-19
DISHMAN PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs374830 45.1%   
Low Rs129527 24.5%   
Sales per share (Unadj.) Rs197.8333.9 59.2%  
Earnings per share (Unadj.) Rs21.240.4 52.5%  
Cash flow per share (Unadj.) Rs34.751.8 67.1%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.80.4 215.7%  
Book value per share (Unadj.) Rs179.9237.1 75.9%  
Shares outstanding (eoy) m80.69585.91 13.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.0 62.6%   
Avg P/E ratio x11.916.8 70.6%  
P/CF ratio (eoy) x7.213.1 55.3%  
Price / Book Value ratio x1.42.9 48.9%  
Dividend payout %9.46.2 152.2%   
Avg Mkt Cap Rs m20,306397,569 5.1%   
No. of employees `0000.817.9 4.6%   
Total wages/salary Rs m5,35525,849 20.7%   
Avg. sales/employee Rs Th19,252.710,956.9 175.7%   
Avg. wages/employee Rs Th6,459.51,447.7 446.2%   
Avg. net profit/employee Rs Th2,064.11,324.3 155.9%   
INCOME DATA
Net Sales Rs m15,961195,636 8.2%  
Other income Rs m2651,553 17.1%   
Total revenues Rs m16,226197,189 8.2%   
Gross profit Rs m4,10339,519 10.4%  
Depreciation Rs m1,0916,680 16.3%   
Interest Rs m9442,626 36.0%   
Profit before tax Rs m2,33431,767 7.3%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m6247,269 8.6%   
Profit after tax Rs m1,71123,645 7.2%  
Gross profit margin %25.720.2 127.3%  
Effective tax rate %26.722.9 116.8%   
Net profit margin %10.712.1 88.7%  
BALANCE SHEET DATA
Current assets Rs m11,018153,645 7.2%   
Current liabilities Rs m9,517120,429 7.9%   
Net working cap to sales %9.417.0 55.4%  
Current ratio x1.21.3 90.7%  
Inventory Days Days110135 81.7%  
Debtors Days Days3564 54.7%  
Net fixed assets Rs m16,304103,909 15.7%   
Share capital Rs m161586 27.5%   
"Free" reserves Rs m12,907138,322 9.3%   
Net worth Rs m14,516138,908 10.4%   
Long term debt Rs m4,1891,800 232.8%   
Total assets Rs m29,805264,544 11.3%  
Interest coverage x3.513.1 26.5%   
Debt to equity ratio x0.30 2,227.9%  
Sales to assets ratio x0.50.7 72.4%   
Return on assets %8.99.9 89.7%  
Return on equity %11.817.0 69.3%  
Return on capital %17.523.8 73.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95297,316 5.1%   
Fx outflow Rs m69740,589 1.7%   
Net fx Rs m4,25556,727 7.5%   
CASH FLOW
From Operations Rs m2,78616,220 17.2%  
From Investments Rs m-1,529-28,768 5.3%  
From Financial Activity Rs m-94119,191 -4.9%  
Net Cashflow Rs m3166,656 4.8%  

Share Holding

Indian Promoters % 61.4 54.1 113.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 8.0 46.5%  
FIIs % 12.7 27.7 45.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.2 216.7%  
Shareholders   46,261 69,601 66.5%  
Pledged promoter(s) holding % 35.8 8.6 417.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   SHASUN PHARMA  WYETH LTD  GSK PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 248 Points Lower; Power and IT Stocks Witness Selling(Closing)

Indian share markets fell sharply during closing hours today and ended deep in the red. The BSE Sensex stood lower by 248 points, while the NSE Nifty closed down by 81 points.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

This PSU Turned into a Rare 100 Bagger. Others May Follow.(The 5 Minute Wrapup)

Nov 27, 2019

The lowest hanging fruit for government to raise capital would be to sell off stakes in non-critical PSUs.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS